News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. completes study on crofelemer for cancer therapy-induced diarrhea in dogs. Results expected to complement positive outcomes. Company plans to file effectiveness study by Q2 2026 -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar Health's crofelemer program targeting intestinal failure shows promising results with reductions in parenteral support for pediatric patients. Company sponsors ELITE PED-GI Congress in Abu Dhabi -
-
